linkedin

Press Releases

Samsung BIO Insight

Talking COVID-19 Vaccine Cooperation with John Rim

THE KOREA COCIETY President's Interview Series Talking COVID-19 Vaccine Cooperation with John Rim President & CEO of Samsung Biologics 


 

Demand for bio-medicines in a rapidly changing global environment is increasing day by day. Amid growing global interest in the COVID-19 vaccine as a critical key to ending the pandemic, Samsung Biologics drew attention from both the media and the industry for its recent agreement for the fill-finish manufacturing of Moderna’s COVID-19 vaccine.

Recently, John Rim, CEO of Samsung Biologics, had an interview with Thomas Byrne, President and CEO of The Korea Society, a nonprofit organization that aims to promote greater awareness, mutual understanding, and cooperation between the U.S. and South Korea.

 

The Korea Society’s “President's Interview Series” particularly explores the economic, financial, and business relations between South Korea and the U.S. In addition to sharing the current outlook of the pharmaceutical industry, CEO John Rim discussed Samsung Biologics' capabilities to manufacture mRNA vaccines, its role in the ongoing pandemic as a leading global CDMO, and its future growth vision.


 

To watch the full interview, please click on the video below.

 

 

To watch the full interview, please click on the video below
 

 

If you want to read about Samsung Biologics’ COVID-19 vaccine agreement with Moderna and our plans to add mRNA vaccine DS production capability to its facilities, please visit our Newsroom for more information.

 


 

THE KOREA COCIETY President's Interview Series Talking COVID-19 Vaccine Cooperation with John Rim President & CEO of Samsung Biologics 


 

Demand for bio-medicines in a rapidly changing global environment is increasing day by day. Amid growing global interest in the COVID-19 vaccine as a critical key to ending the pandemic, Samsung Biologics drew attention from both the media and the industry for its recent agreement for the fill-finish manufacturing of Moderna’s COVID-19 vaccine.

Recently, John Rim, CEO of Samsung Biologics, had an interview with Thomas Byrne, President and CEO of The Korea Society, a nonprofit organization that aims to promote greater awareness, mutual understanding, and cooperation between the U.S. and South Korea.

 

The Korea Society’s “President's Interview Series” particularly explores the economic, financial, and business relations between South Korea and the U.S. In addition to sharing the current outlook of the pharmaceutical industry, CEO John Rim discussed Samsung Biologics' capabilities to manufacture mRNA vaccines, its role in the ongoing pandemic as a leading global CDMO, and its future growth vision.


 

To watch the full interview, please click on the video below.

 

 

To watch the full interview, please click on the video below
 

 

If you want to read about Samsung Biologics’ COVID-19 vaccine agreement with Moderna and our plans to add mRNA vaccine DS production capability to its facilities, please visit our Newsroom for more information.

 


SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved